Research programme: cancer therapeutics - Joyant Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - Joyant Pharmaceuticals

Alternative Names: JP 1201; JP-1036

Latest Information Update: 16 Feb 2011

Price : $50

At a glance

  • Originator Joyant Pharmaceuticals
  • Class Amides; Peptides; Small molecules
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Cancer; Non-small cell lung cancer

Most Recent Events

  • 21 Apr 2010 Preclinical pharmacodynamics data presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
  • 16 Apr 2008 Preclinical trials in Lung cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top